NASDAQ: CNSY · Houston, TX

Platform · Company description

Plus Therapeutics
is now
Cerenome.

Diagnostics, therapeutics and data, described by the company as one CNS oncology platform.

Figure 1Three capabilities, one system
DIAGNOSTICSTHERAPEUTICSDATA INSIGHTS
Nasdaq ticker
CNSY was PSTV · Aug 3, 2026

Fig. 02 · CNSide Diagnostics

A spinal fluid test
for CNS cancer,
in clinical use.

A laboratory-developed test. Performed at more than 120 U.S. cancer institutions, per the company.

Figure 2Stage labels · company website
INDEVELOPMENTLAUNCHINGSOONCOMMERCIAL Detection & monitoringMolecular profilingTargeted biomarkers Fill shows the website's stage; not a forecast.
Tests since 2020
11,000+ per the company

Fig. 03 · REYOBIQ · Investigational

Phase 2 enrollment
complete in recurrent
glioblastoma.

Investigational and not FDA-approved. Topline data expected mid‑2027.

Figure 3ReSPECT-GBM · Phase 2 portion
● 32 treated at the Phase 2 dose ○ 34 planned; enrollment closed at 32 after a statistical review (company)
Topline data
Mid-2027 expected, per company

Fig. 04 · CNSide Coverage

Payer coverage
reaching ~164M lives.

222 tests billed in Q3. Contracted commercial and Medicare Advantage lives, per the company.

Figure 4Contracted covered lives
~158MSEP 22~164MOCT 8~200MEARLY 2027COMPANY TARGET
Q3 gross billings
$1.55M unaudited · per company
Read the Investor Overview
Forward-looking statements, including trial timing and results and CNSide coverage, reimbursement and billing, involve risks; actual results may differ materially. REYOBIQ is investigational and not FDA-approved. Billings are unaudited gross billings. See SEC filings for risk factors.